Efficacy of Ivermectin in COVID-19

INTERVENTION It will be a randomized controlled trial which will be done on COVID-19 patients
proven by PCR fulfilling the criteria (asymptomatic/mild to moderate severity). They will be
divided into two groups after randomization. Group A will be administered Ivermectin single
dose of 12grams along with Chloroquine as per existing hospital guidelines and group B will
be given Chloroquine alone. Dose of Ivermectin to be repeated at 1 week if PCR stays
negative. PCR will be done on alternate days (48, 96 and 144hours) and the duration at which
the PCR becomes negative will be compared. Dose of drug subject to change in accordance with
patient response or possible side effect.

ELIGIBILITY CRITERIA INCLUSION CRITERIA

In order to be eligible to participate in this study, an individual must meet all of the
following criteria:

Provision of signed and dated informed consent form Stated willingness to comply with all
study procedures and availability for the duration of the study Male or female, aged 15 to 65
years In good general health with no or mild symptoms of Corona virus disease PCR positive
for SARS-Cov-2. Ability to take oral medication and be willing to adhere to the drug intake
regimen EXCLUSION CRITERIA

An individual who meets any of the following criteria will be excluded from participation in
this study:

Severe symptoms likely attributed to Cytokine Release Storm. Malignant diseases, diabetes
mellitus, chronic kidney disease and cirrhosis liver with CPT class B or C.